Dr. Alex Morgan brings a broad analytical perspective to biotechnology, healthcare innovation, and life sciences strategy. With experience spanning research, industry analysis, and market intelligence, Alex examines how scientific progress, capital flows, and policy decisions intersect. At The Catalyst Brief, Alex focuses on connecting developments across domains to surface the strategic implications that matter most to industry leaders.
134 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyThe FDA’s decision not to review Moderna’s mRNA-based flu vaccine has elicited widespread responses from industry experts and regulators. This controversy occurs amid a broader crisis in communication within the FDA, affecting multiple companies and complicating the regulatory landscape for novel vaccine technologies.
Dr. Alex MorganFeb 13, 2026
Healthcare InvestmentThis post explores the recent $210 million funding round for Talkiatry aiming to leverage AI for patient engagement, alongside Big Health's $24 million raise that underscores renewed investor optimism in digital therapeutics. Additionally, insights into the reassessment of the Apple Watch hypertension feature provide a backdrop for innovations in health technology.
Dr. Alex MorganFeb 12, 2026
Biopharmaceutical IndustryAs the biopharmaceutical industry continues to evolve rapidly, understanding the nuances of the job market and hiring landscape remains essential for professionals aiming to navigate this complex environment successfully. Insights from industry talent acquisition and recruiting experts reveal key trends that will inform career strategies in 2026.
Dr. Alex MorganFeb 12, 2026
Biopharmaceutical IndustryPharmaEssentia’s new manufacturing center in Puerto Rico represents a substantial move to shore up drug production capacity for the U.S. market. This investment points to broader trends in pharmaceutical supply chain resilience and regional manufacturing expansion.
Dr. Alex MorganFeb 11, 2026
Biopharmaceutical IndustryBiogen, a major player in the biopharmaceutical sector, is navigating an evolving landscape where generic drugs exert unprecedented pressure on flagship products. To sustain its market position and rekindle growth, the company is leveraging a congested Phase 3 pipeline and exploring strategic partnerships that may shape its future trajectory.
Dr. Alex MorganFeb 6, 2026
Regulatory & PolicyAs Alicia Jackson assumes leadership of ARPA-H, shifts in organizational priorities are evident with the recent layoffs affecting key personnel tasked with translating research advancements into commercial applications. This move signifies possible strategic recalibrations within the agency as it navigates its next phase.
Dr. Alex MorganFeb 6, 2026
Biopharmaceutical IndustryIn a move illustrating the dynamic nature of early cancer drug development, Novartis is streamlining its oncology portfolio to enhance focus on the most promising candidates. Despite cutting multiple projects, the company reaffirms commitment to innovation through selective acquisitions and partnerships, indicating a strategic refinement aimed at long-term success in the oncology sector.
Dr. Alex MorganFeb 5, 2026
Medical TechnologyJake Leach assumed leadership of DexCom with a mission to revitalize the company’s impact in diabetes management. He advocates that type 2 diabetics on GLP-1 weight loss drugs should also utilize CGMs, reflecting a growing intersection of diabetes technologies and therapies. This perspective highlights the evolving standards in diabetes care and DexCom’s innovative role within it.
Dr. Alex MorganFeb 5, 2026
AI in Drug DiscoveryEpic's AI Charting technology leverages advanced AI methodologies to automate and enhance electronic health record documentation. This development could alter the landscape of ambient scribe services and redefine clinician workflows.
Dr. Alex MorganFeb 4, 2026
Regulatory & PolicyIn a recent legislative development, the U.S. President signed a spending package into law that includes the reauthorization of the FDA's rare pediatric disease priority review voucher program, a key initiative incentivizing drug development for rare diseases affecting children. Additionally, the bill funds reforms targeted at pharmacy benefit managers (PBMs), marking a significant policy shift with potential wide-reaching implications for drug approval processes and the pharmaceutical supply chain.
Dr. Alex MorganFeb 4, 2026
Biotech InnovationAs the pandemic winds down, BioNTech and Moderna's once parallel trajectories have diverged significantly. BioNTech’s diversified modality strategy contrasts with Moderna’s mRNA-centric pipeline, highlighting strategic shifts in how these companies leverage their COVID-19 windfalls to fuel future growth.
Dr. Alex MorganFeb 3, 2026
Biopharmaceutical IndustryRecent data from UnitedHealth underscores key trends affecting the Medicare Advantage sector, signaling shifts in revenue coding strategies and broader market impacts. This analysis explores the company's forecast implications and the potential effects on healthcare finance and policy.
Dr. Alex MorganFeb 2, 2026